This is a randomized controlled trial comparing 3 strategies to improve wellness behaviors and clinical goals for diabetes type 2(DM2) Medicaid patients. A patient interactive cell phone disease management system plus a community health worker (CHW) is superior to either a cell phone system or a CHW alone to activate DM2 Medicaid patients to improve a composite of 7 Wellness Behaviors and 6 Clinical Goals.
Full Title of Study: “Changing the Healthcare Delivery Model:A Community Health Worker/Mobile Chronic Care Team Strategy”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Health Services Research
- Masking: None (Open Label)
- Study Primary Completion Date: August 2016
This is a randomized controlled trial comparing 3 strategies to improve wellness behaviors and clinical goals for DM2 Medicaid patients with uncontrolled DM. – Group 1 will be assisted by the Voxiva Care4Life mobile health disease management program (C4L) provided on the patient's cell phone. – Group 2 will be assisted by CHWs who are members of the outpatient medical home health team. – Group 3 will be assisted by both the Voxiva Care4Life mHealth disease management system (C4L) and a CHW. Hypotheses: 1. A patient interactive cell phone disease management system plus a community health worker (CHW) is superior to either a cell phone system or a CHW alone to activate DM2 Medicaid patients to improve a composite of 7 Wellness Behaviors and 6 Clinical Goals. 2. A patient interactive cell phone disease management system will activate Medicaid patients with type 2 diabetes (DM2) to improve the composite of 7 wellness behaviors and 6 clinical outcomes by 25% or greater compared to baseline Expected Outcomes: Primary outcomes: 1. Superior improvement over baseline of the composite of Wellness Behaviors and Clinical Outcomes in the CHW plus C4L group compared to the CHW alone and cell phone alone groups. 2. Improvement by 25% or greater over baseline of the composite of Wellness Behaviors and Clinical Outcomes for patients using C4L alone. Secondary outcomes: Improvement in both clinical and behavior endpoints. Endpoints to be compared across the three treatment arms include: 1. mean HbA1c, 2. mean LDLc Cholesterol 3. average BP if hypertensive 4. Patient distress measured with Fisher Brief Diabetes Distress Screening Instrument 4) Medication adherence measured with Morisky Medication Adherence Survey 5) Healthcare utilization: ER, acute clinic visits, hospitalizations Anticipated results and impact on healthcare: Mobile health has great potential to enhance DM2 patient health behaviors and clinical outcomes both alone and, even better, with assistance of a CHW. mHealth systems can be provided to a wide range of urban and rural DM2 patients resulting in an affordable, a more efficient patient-driven/centered health delivery system.
- Behavioral: mobile health care application
- mobile health application for cell phones to assist patients in managing their diabetes.
- Behavioral: CHWs and mobile health care application
- CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.
- Behavioral: Community Health Worker (CHW)
- CHWs assist patients in managing their diabetes in various ways.
Arms, Groups and Cohorts
- Active Comparator: Mobile health care application
- Patients will be assisted with managing their health by a cell phone application used to promote self care for patients with diabetes.
- Active Comparator: Community Health Worker (CHW)
- CHWs assist study patients in managing there health care in various ways.
- Experimental: CHWs and mobile health care application
- Patients will receive assistance in managing their health from both CHWs and the mobile health cell phone application
Clinical Trial Outcome Measures
- Change From Baseline in the Unmet Behaviors/Goals That Were Not Achieved at Year 1
- Time Frame: baseline and 1 year
- The study staff will determine the status of the 13 behaviors/goals for the year prior to study enrollment. Our primary endpoint will be the mean change after 1 year in number of behaviors/goals met from baseline.
- Change in Distress From Baseline as Measured With Fisher Brief Diabetes Distress Screening Instrument
- Time Frame: Baseline and 1 year
- Participants completed the Fisher Brief Diabetes Screening Instrument at baseline and after 1 year of intervention. The instrument consists of 4 questions regarding how participants feel about dealing with diabetes. They are answered using a scale that goes from 1-6, 1= not a bother and 6=very bothersome. Range 4-24. Low distress < 12 : moderate / high distress > or = 12.
- Change in Hemoglobin A1C
- Time Frame: Baseline and 1 year
- Change in HbA1c after 1 year from baseline
- Change in Medication Adherence
- Time Frame: baseline and 1 year
- Medication adherence Improvement from baseline after 1 year as measured by the Morisky Medication Adherence Survey. Range 1-4 . 1= least adherent , 4= most adherent
Participating in This Clinical Trial
- Age 21 to 75 years old – Medicaid insurance coverage, Medicare insurance coverage or Affordable Health Care Act insurance coverage – Fluent in English or Spanish and able to read a text message – Diagnosed with diabetes mellitus type 2 and A1C is > 8% Acceptable values will be either : – A1c obtained within one month prior to baseline (as long as there were no diabetes changes made during that month) or – A new A1c measured at the baseline screening visit. – Meets < 10 of the wellness behaviors and clinical goals if diagnosed with hypertension Meets < 9 of the wellness behaviors and clinical goals if not diagnosed with hypertension Exclusion Criteria:
- Stage 5 chronic kidney disease or end stage renal disease on dialysis – Terminal illness (expected survival of less than one year) – Severe dementia or uncontrolled mental illness – Gestational diabetes mellitus – Use of an insulin pump – Inability to use a cellular phone – Unable to use software application on cellular phone – Pregnant or planning to get pregnant
Gender Eligibility: All
Minimum Age: 21 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- George Washington University
- Provider of Information About this Clinical Study
- Overall Official(s)
- Richard Katz, MD, Principal Investigator, Medical Faculty Assoc. Inc, GWUniv
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.